Shares of Extendicare Inc. (TSE:EXE – Get Free Report) have been given an average rating of “Buy” by the eight ratings firms that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating, four have issued a buy rating and three have issued a strong buy rating on the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is C$23.86.
EXE has been the topic of a number of recent analyst reports. Canaccord Genuity Group lifted their price objective on Extendicare from C$20.00 to C$22.50 in a research note on Thursday, December 4th. CIBC raised their target price on Extendicare from C$18.00 to C$22.00 in a report on Thursday, November 13th. Natl Bk Canada raised Extendicare to a “strong-buy” rating in a research report on Wednesday, December 3rd. BMO Capital Markets upgraded Extendicare from a “hold” rating to an “outperform” rating and upped their price target for the stock from C$21.00 to C$24.00 in a report on Thursday, December 4th. Finally, Royal Bank Of Canada raised Extendicare from a “hold” rating to a “moderate buy” rating and increased their price objective for the company from C$15.00 to C$25.00 in a research report on Thursday, December 4th.
Check Out Our Latest Report on Extendicare
Extendicare Stock Performance
Extendicare Dividend Announcement
The business also recently declared a monthly dividend, which was paid on Monday, November 17th. Shareholders of record on Monday, November 17th were given a $0.042 dividend. This represents a c) annualized dividend and a yield of 2.3%. The ex-dividend date was Friday, October 31st. Extendicare’s dividend payout ratio (DPR) is currently 46.60%.
Extendicare Company Profile
Extendicare Inc, operating solely in Canada, is the largest private-sector owner and operator of long-term care (LTC”) homes and one of the largest private-sector providers of publicly funded home health care services.
Featured Stories
- Five stocks we like better than Extendicare
- Why Are These Companies Considered Blue Chips?
- Dave & Buster’s Reversal Is in PLAY After Double-Bottom Breakout
- P/E Ratio Calculation: How to Assess Stocks
- 3 Finance Stocks to Buy on Rising 10-Year Treasury Rates
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Disney’s $1 Billion Deal Brings Its Magic to OpenAI
Receive News & Ratings for Extendicare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Extendicare and related companies with MarketBeat.com's FREE daily email newsletter.
